West Pharmaceutical Services (WST) Other Non-Current Liabilities (2009 - 2026)

West Pharmaceutical Services has reported Other Non-Current Liabilities for 18 years, with the latest figure at $89.9 million in Q2 2026.

• Quarterly Other Non-Current Liabilities rose 27.7% year-over-year to $89.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $89.9 million (up 27.7% YoY) and the FY2025 annual result came in at $75.2 million, up 20.9% from the prior year.
• Other Non-Current Liabilities climbed to $89.9 million in Q2 2026 per WST's latest filing, from $87.6 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $89.9 million in Q2 2026 and troughed at $33.9 million in Q3 2022.
• A 5-year average of $61.0 million and a median of $60.4 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities surged 62.54% in 2023, then advanced 3.76% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $51.6 million in 2022, then advanced by 13.37% to $58.5 million in 2023, then grew by 6.32% to $62.2 million in 2024, then rose by 20.9% to $75.2 million in 2025, then climbed by 19.55% to $89.9 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $89.9 million, $87.6 million, and $75.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.